Scilife Training | FDA 483 responses: what the new draft guidance means for you

With the FDA’s new draft guidance on responding to Form 483 observations, expectations are shifting.

What used to be “acceptable” responses may no longer hold up.

In this session, we’ll unpack what these changes really mean in practice and how to prevent quality issues in the first place.

Training | FDA 483 responses: what the new draft guidance means for you

April 28, 2026 | 11:00H (CEST)

We’ll explore:

• What the new FDA draft guidance on 483 responses actually expects from you
• How to approach audits with a clearer understanding of the inspector’s mindset
• The systemic gaps that commonly lead to repeat observations
• Practical strategies to strengthen your responses and stay compliant
• How to drive management engagement and build stronger CAPAs

Register here for free

You’ll hear from Antiksha Joshi, Pharmaceutical QMS Consultant and Angel Buendía, Scilife’s Knowledge Manager, will be moderating this online session.

It’s not just about responding to observations but building a more robust quality system!